Search alternatives:
significant gram » significant gap (Expand Search), significant group (Expand Search), significant bias (Expand Search)
greater decrease » greater increase (Expand Search), greater increases (Expand Search), rate decreased (Expand Search)
teer decrease » mean decrease (Expand Search)
gram based » graph based (Expand Search), grade based (Expand Search), team based (Expand Search)
significant gram » significant gap (Expand Search), significant group (Expand Search), significant bias (Expand Search)
greater decrease » greater increase (Expand Search), greater increases (Expand Search), rate decreased (Expand Search)
teer decrease » mean decrease (Expand Search)
gram based » graph based (Expand Search), grade based (Expand Search), team based (Expand Search)
-
161
-
162
Table1_Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis.docx
Published 2021“…<p>Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.…”
-
163
Summary of bilateral risk-reducing mastectomy procedures performed throughout the study period.
Published 2023Subjects: -
164
-
165
-
166
-
167
-
168
Reconstructive surgery data in patients undergoing BRRM over the entire study period.
Published 2023Subjects: -
169
Epac activation with 8CPT-AM induced RLC phosphorylation in the perfused hearts.
Published 2025Subjects: -
170
-
171
Schematic summary of the proposed role of Epac1 in the regulation of myofilament function.
Published 2025Subjects: -
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
DataSheet1_Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis.docx
Published 2021“…<p>Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.…”